CAJ | 학술논문

目的：探讨血清中miR-143的表达在乙型肝炎病毒感染相关性肝病的诊断及预后评估中的应用价值。方法收集79例慢性乙型肝炎、61例乙型肝炎肝硬化、67例HBV相关性肝癌患者的一般临床资料及血清样本，同时收集30例健康体检者的一般临床资料及血清样本。分别提取各血清样本中的microRNA，再经实时定量PCR检测各血清中miR-143的表达水平，分析miR-143在各组之间的表达差异。结果与健康对照组相比，血清miR-143的表达量在HBV相关性肝癌组中表达量下降，且差异具有统计学意义（P＜0.001），在慢性乙型肝炎组及乙型肝炎肝硬化组中的表达量亦下调，但差异无统计学意义。在区分HBV相关性肝癌组与健康对照组时，受试者工作曲线分析结果显示单用血清miR-143的曲线下面积为0.890（95%CI：0.810～0.945），敏感性为83.6%，特异性为83.3%；单用AFP的曲线下面积为0.836（95%CI：0.742～0.907），敏感性为70.7%，特异性为96.7%；联合血清miR-143与AFP时的曲线下面积为0.945（95% CI：0.875～0.983），敏感性为89.7%，特异性为96.7%。结论血清miR-143有可能成为一种新的无创性HBV相关性肝癌诊断的血清学标记物。
목적：탐토혈청중miR-143적표체재을형간염병독감염상관성간병적진단급예후평고중적응용개치。방법수집79례만성을형간염、61례을형간염간경화、67례HBV상관성간암환자적일반림상자료급혈청양본，동시수집30례건강체검자적일반림상자료급혈청양본。분별제취각혈청양본중적microRNA，재경실시정량PCR검측각혈청중miR-143적표체수평，분석miR-143재각조지간적표체차이。결과여건강대조조상비，혈청miR-143적표체량재HBV상관성간암조중표체량하강，차차이구유통계학의의（P＜0.001），재만성을형간염조급을형간염간경화조중적표체량역하조，단차이무통계학의의。재구분HBV상관성간암조여건강대조조시，수시자공작곡선분석결과현시단용혈청miR-143적곡선하면적위0.890（95%CI：0.810～0.945），민감성위83.6%，특이성위83.3%；단용AFP적곡선하면적위0.836（95%CI：0.742～0.907），민감성위70.7%，특이성위96.7%；연합혈청miR-143여AFP시적곡선하면적위0.945（95% CI：0.875～0.983），민감성위89.7%，특이성위96.7%。결론혈청miR-143유가능성위일충신적무창성HBV상관성간암진단적혈청학표기물。
Objective To explore the value of the serum microRNA-143 expression in diagnostic and prognostic assessment of HBV associated liver disease. Methods The serum samples and general clinical data of 79 chronic hepatitis B (CHB) patients, 61 HBV associated liver cirrhosis (HBV-LC) patients, 67 HBV associated hepatocellular carcinoma (HBV-HCC) patients and 30 healthy individuals were collected in this study. The expression of miR-143 was explored by using real-time quantitative PCR. Statistical method was used to analysis the different expressions of miR-143 in different groups. Results The level of serum miR-143 was significantly decreased in HBV-HCC patients compared with healthy individuals (P<0.001), while the levels of miR-143 in CHB and HBV-LC patients didn't have significantly different compared with healthy individuals. ROC curve analysis indicated that serum miR-143 was useful in differentiating HBV-HCC from healthy individuals, with an AUC value of 0.890 (95% CI: 0.810-0.945; sensitivity=83.6%; specificity=83.3%). The AUC of AFP was 0.836(95%CI:0.742-0.907;sensitivity=70.7%;specificity=96.7%) while the AUC of serum miR-143 combined with AFP was 0.945 (95% CI: 0.875-0.983; sensitivity=89.7%; specificity=96.7%). Conclusion Serum miR-143 can serve as a novel noninvasive biomarker for diagnosis of HBV-HCC.